KAUST Discovery Professor Jesper Tegnér collaborated with UK researchers to develop algorithms explaining decision-making in insects and rats. Assoc. Prof. Robert Hoehndorf's lab introduced a tool for identifying genetic variants linked to rare diseases based on patient symptoms. KAUST scientists also studied monkeypox infection of human skin using stem cells and marine microbiome adaptation to thermal changes. Why it matters: These diverse research projects highlight KAUST's contributions to computational biology, virology, and marine science, advancing knowledge with implications for healthcare and environmental challenges.
A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.
Malaria No More, the Crown Prince Court of Abu Dhabi, and the Reaching the Last Mile program launched the Institute for Malaria and Climate Solutions (IMACS) to combat malaria amidst climate change. Mohamed Bin Zayed University for Artificial Intelligence (MBZUAI) joined as a technical partner, providing research support leveraging AI and data science. The initiative aims to develop and implement AI-driven strategies to address the impact of climate change on malaria transmission. Why it matters: This partnership highlights the UAE's commitment to using AI for global health challenges, particularly in combating climate-sensitive diseases like malaria.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
KAUST researchers used cryogenic electron microscopy (cryo-EM) to study the 3D structure of protein complexes involved in DNA replication and repair. They investigated the interaction between the Y-family TLS polymerase Pol K and mono-ubiquitylated PCNA. The study revealed that DNA binding is required for Pol K to form a rigid, active complex with PCNA. Why it matters: Understanding these structural interactions may provide insights into cancer development and drug resistance mechanisms.
KAUST researchers analyzed bacterial communities from Deception Island, Antarctica, finding heat-loving bacteria with potential for oil cleanup. Postdoctoral student Junia Schultz is now characterizing the microbiome of extreme terrestrial environments in Saudi Arabia, including volcanoes and deserts. These extremophiles secrete surfactants to break down oil and absorb it into their cells for degradation. Why it matters: This research could lead to efficient and safe methods for cleaning up oil contamination using extremophiles found in both Antarctica and Saudi Arabia.
KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.